Athersys (ATHX) Prices 22.25M Share Common Offering at $2.25/Sh

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. ANT
3. SPY
4. FFAI
5. FFR
6. META
7. FICO
8. CART
9. LLY
10. TSLA

Go back to Athersys (ATHX) Prices 22.25M Share Common Offering at $2.25/Sh

After-Hours Stock Movers 04/15: (RCUS) (AM) (BBBY) Higher; (ATHX) (CALA) (LAKE) Lower (more...)

April 15, 2020 6:03 PM EDT

Today's After-Hours Stock Movers

Arcus Biosciences (NYSE: RCUS) 47.5% HIGHER; Gilead (NASDAQ: GILD) is considering acquiring a stake in Arcus Biosciences (NYSE: RCUS), according to Bloomberg, citing people familiar with the matter.

Antero Midstream (NYSE: AM) 16.8% HIGHER; said first quarter 2020 dividend is unchanged as compared to the fourth quarter of 2019.

Bed Bath & Beyond (NASDAQ: BBBY) 14.4% HIGHER; reported Q4 EPS... More

Athersys (ATHX) intends to offer for sale $50 million of shares of its common stock

April 15, 2020 4:28 PM EDT

Athersys, Inc. (NASDAQ: ATHX) (Athersys) announced today that it intends to offer for sale $50 million of shares of its common stock, par value $0.001 per share (Common Stock), in an underwritten public offering. In addition, Athersys expects to grant the underwriters a 30-day option to... More

Pre-Open Movers 04/15: (JBLU) (UEPS) (ATHX) Higher; (CVA) (IVZ) (ILMN) Lower (more...)

April 15, 2020 9:30 AM EDT

Today's Pre-Open Stock Movers

Covanta Holding (NYSE: CVA) 12.1% LOWER; Withdraws 2020 Guidance. Stifel downgraded Covanta (NYSE: CVA) from Buy to Sell with a price target of $6.50 (from $17.50).

JetBlue Airways (NASDAQ: JBLU) 9% HIGHER; To particulate in Treasury payroll support program

Invesco (NYSE: IVZ) 7.5% LOWER; Citi downgraded from Neutral to Sell with a price target of $5.50 (from... More

Athersys (ATHX) Reports FDA Approval to Begin Phase 2 Trial Evaluating MultiStem Cell Therapy in Trauma Patients

April 15, 2020 6:01 AM EDT

Athersys, Inc. (NASDAQ: ATHX) announced today that the U.S. Food and Drug Administration (FDA) has authorized an Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating Athersys MultiStem® cell therapy for early treatment of traumatic injuries and the subsequent complications that result following severe trauma. Memorial Hermann-Texas Medical Center in Houston, Texas, one of the busiest Level 1 trauma centers in the United States, intends to conduct the trial. The study represents another important application of the companys MultiStem cell therapy in the critical care area, targeting the severe inflammatory responses... More